La Trobe

File(s) stored somewhere else

Please note: Linked content is NOT stored on La Trobe and we can't guarantee its availability, quality, security or accept any liability.

Dimethyl fumarate and its esters: A drug with broad clinical utility?

journal contribution
posted on 19.11.2020, 05:46 by S Kourakis, CA Timpani, Judy de Haan, N Gueven, D Fischer, E Rybalka
© 2020 by the authors. Licensee MDPI, Basel, Switzerland. Fumaric acid esters (FAEs) are small molecules with anti‐oxidative, anti‐inflammatory and immune‐modulating effects. Dimethyl fumarate (DMF) is the best characterised FAE and is approved and registered for the treatment of psoriasis and Relapsing‐Remitting Multiple Sclerosis (RRMS). Psoriasis and RRMS share an immune‐mediated aetiology, driven by severe inflammation and oxidative stress. DMF, as well as monomethyl fumarate and diroximel fumarate, are commonly prescribed first‐line agents with favourable safety and efficacy profiles. The potential benefits of FAEs against other diseases that appear pathogenically different but share the pathologies of oxidative stress and inflammation are currently investigated.

Funding

This research received no external funding (funding was provided by Victoria University and University Children's Hospital Basel commercialization partnership scheme).

History

Publication Date

13/10/2020

Journal

Pharmaceuticals

Volume

13

Issue

10

Article Number

ARTN 306

Pagination

15p.

Publisher

MDPI

ISSN

1424-8247

Rights Statement

The Author reserves all moral rights over the deposited text and must be credited if any re-use occurs. Documents deposited in OPAL are the Open Access versions of outputs published elsewhere. Changes resulting from the publishing process may therefore not be reflected in this document. The final published version may be obtained via the publisher’s DOI. Please note that additional copyright and access restrictions may apply to the published version.

Licence

Exports